Dynamic changes of phenotype and function of natural killer cells in peripheral blood before and after thermal ablation of hepatitis B associated hepatocellular carcinoma and their correlation with tumor recurrence.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
30 May 2023
Historique:
received: 10 03 2022
accepted: 06 04 2023
medline: 1 6 2023
pubmed: 31 5 2023
entrez: 30 5 2023
Statut: epublish

Résumé

Thermal therapy induces an immune response in patients with hepatocellular carcinoma (HCC), but the dynamic characteristics of the natural killer (NK) cell immune response post-thermal ablation remain unclear. We conducted a prospective longitudinal cohort study to observe the dynamic changes of phenotype and function of NK cells in peripheral blood before and after thermal ablation of hepatitis B-associated HCC and their correlation with tumor recurrence. Fifty-six patients clinically and pathologically confirmed with hepatitis B-associated HCC were selected for thermal ablation. Peripheral blood was collected on day 0, day 7, and month 1. NK cell subsets, receptors, and killing function were detected by flow cytometry, and the LDH levels were examined. Overall recurrence and associated variables were estimated using Kaplan-Meier, log-rank, and Cox proportional-hazards analyses. The frequency of CD3 Thermal ablation increased the frequency and function of CD3

Sections du résumé

BACKGROUND BACKGROUND
Thermal therapy induces an immune response in patients with hepatocellular carcinoma (HCC), but the dynamic characteristics of the natural killer (NK) cell immune response post-thermal ablation remain unclear. We conducted a prospective longitudinal cohort study to observe the dynamic changes of phenotype and function of NK cells in peripheral blood before and after thermal ablation of hepatitis B-associated HCC and their correlation with tumor recurrence.
METHODS METHODS
Fifty-six patients clinically and pathologically confirmed with hepatitis B-associated HCC were selected for thermal ablation. Peripheral blood was collected on day 0, day 7, and month 1. NK cell subsets, receptors, and killing function were detected by flow cytometry, and the LDH levels were examined. Overall recurrence and associated variables were estimated using Kaplan-Meier, log-rank, and Cox proportional-hazards analyses.
RESULTS RESULTS
The frequency of CD3
CONCLUSION CONCLUSIONS
Thermal ablation increased the frequency and function of CD3

Identifiants

pubmed: 37254046
doi: 10.1186/s12885-023-10823-4
pii: 10.1186/s12885-023-10823-4
pmc: PMC10228897
doi:

Substances chimiques

Granzymes EC 3.4.21.-
Perforin 126465-35-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

486

Informations de copyright

© 2023. The Author(s).

Références

Ann Transl Med. 2016 Mar;4(6):118
pubmed: 27127771
J Leukoc Biol. 2018 Feb 22;:
pubmed: 29469956
Gastroenterology. 2010 May;138(5):1931-42
pubmed: 20060829
Hum Immunol. 2009 Jul;70(7):477-86
pubmed: 19332094
Cancers (Basel). 2021 Apr 02;13(7):
pubmed: 33918125
J Clin Med. 2019 Mar 19;8(3):
pubmed: 30893948
Ann Surg. 2006 Mar;243(3):321-8
pubmed: 16495695
Immunol Res. 2012 Apr;52(1-2):139-56
pubmed: 22442005
Cancer Commun (Lond). 2019 Apr 29;39(1):22
pubmed: 31030667
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Immunol. 2018 Apr 1;200(7):2229-2230
pubmed: 29555675
Cancers (Basel). 2021 Nov 18;13(22):
pubmed: 34830949
Oncoimmunology. 2019 May 25;8(8):1615818
pubmed: 31413924
Immunotherapy. 2019 Oct;11(14):1231-1251
pubmed: 31422725
J Hepatol. 2021 Oct;75(4):960-974
pubmed: 34256065
Clin Transl Immunology. 2021 Oct 05;10(10):e1346
pubmed: 34631057
Cancer Res. 2003 Oct 1;63(19):6496-500
pubmed: 14559842
Immunol Invest. 1995 Mar;24(3):499-507
pubmed: 7540593
Cancer Immunol Immunother. 2007 Jan;56(1):95-100
pubmed: 16547704
Arch Pharm Res. 2019 Jul;42(7):591-606
pubmed: 30895524
J Gastroenterol. 2010 Apr;45(4):451-8
pubmed: 19936602
Clin Cancer Res. 2006 Aug 15;12(16):4822-31
pubmed: 16914567
Nihon Rinsho. 2017 Feb;75(2):306-311
pubmed: 30562869
Curr Opin Immunol. 2015 Feb;32:71-7
pubmed: 25615701
Immunology. 2011 May;133(1):94-104
pubmed: 21342183
J Transl Med. 2017 Jan 31;15(1):23
pubmed: 28137271
Eur Radiol. 2019 May;29(5):2679-2689
pubmed: 30560364
Hum Immunol. 2015 May;76(5):385-91
pubmed: 25305457
Mol Immunol. 2004 Jul;41(6-7):569-75
pubmed: 15219995
Sci Rep. 2017 Sep 4;7(1):10376
pubmed: 28871164
Hepatology. 2013 Apr;57(4):1448-57
pubmed: 23174905
Nat Med. 2011 Jun;17(6):700-7
pubmed: 21552268
J Surg Res. 2011 Dec;171(2):637-49
pubmed: 20828749

Auteurs

Hai-Yan Wang (HY)

Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. m13911237263@163.com.
Biomedical Information Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. m13911237263@163.com.

Xiong-Wei Cui (XW)

Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.

Yong-Hong Zhang (YH)

Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Biomedical Information Center, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.

Yu Chen (Y)

Fourth Department of Liver Disease (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, China.

Ning-Ning Lu (NN)

Center of Interventional Oncology and Liver Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.

Li Bai (L)

Fourth Department of Liver Disease (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, China.

Zhong-Ping Duan (ZP)

Fourth Department of Liver Disease (Difficult & Complicated Liver Diseases and Artificial Liver Center), Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China. duan@ccmu.edu.cn.
Beijing Municipal Key Laboratory of Liver Failure and Artificial Liver Treatment Research, Beijing, China. duan@ccmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH